Background
Lung cancer is the second most commonly diagnosed malignancy in men and the third most commonly diagnosed malignancy in women worldwide. 1 Lung cancer can be classified two major histological groups: small cell lung cancer and non-smallcell lung cancer (NSCLC). NSCLC accounts for more than 80% of all lung cancers, whereas 15%-20% is small cell lung cancer. 2, 3 NSCLC includes adenocarcinoma (ADC), squamous cell carcinoma (SCC), and large-cell carcinoma, within them, ADC accounts for 40%, SCC for 25%-30%, and large-cell carcinoma for 10%-15%. 4, 5 Lung carcinogenesis is related to silencing of tumor suppressor genes and activation of oncogenes. Accumulating data indicate that hypermethylation in CpG-rich promoter regions of many suppressor genes can contribute to the development and progression of a variety of cancers.
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Zhang et al of cell death pathways, therefore they were named "DeathAssociated Protein or DAP genes. 9 One of the genes isolated by the TKO approach encoded a calcium calmodulin regulated serine/threonine kinase and was named DAP kinase (DAPk1 or DAPK). 10, 11 Further investigation indicated that DAPK plays an important role in apoptotic and autophagic cell death, [12] [13] [14] tumor progression suppression, and metastasis suppression. [15] [16] [17] [18] [19] Last two decades, a number of studies showed that DAPK loss by its promoter hypermethylation was associated with the development and progression of NSCLC. However, the results from individual studies were inconsistent due to small size of samples. In the present study, 28 relevant studies were pooled, and a meta-analysis was performed to evaluate the clinicopathological significance of DAPK promoter hypermethylation in NSCLC.
Methods
search strategy and selection criteria
The following electronic databases were screened for relevant articles without any language restrictions: PubMed We used the following keywords: "DAPK methylation", "NSCLC", "Non-small-cell lung cancer", and "lung cancer". A search of PubMed yielded 65 articles, Embase yielded 101, and Web Science yielded 138 articles. The included criteria were as follows: (1) the association between DAPK methylation and the clinicopathological significance of NSCLC; (2) the association of DAPK and prognosis in patients with NSCLC. After screening by titles and abstracts, 38 relevant articles were included for full text review. The following exclusion criteria were used: (1) the same population or overlapping database; (2) conference abstracts containing insufficient data reviews, editorials, letters, case reports, and expert opinion; (3) the studies utilized cell lines. After evaluation, 28 articles fulfilled the entry criteria of this meta-analysis. The detailed information of 28 relevant articles was listed in Table 1 .
Data extraction and study assessment
Two reviewers (YZ and JW) extracted data from selected studies independently by using a standardized data extraction form including the following items: first author's name, year of publication, country, number of patients, histology, stage of NSCLC, smoking status of patients with NSCLC, method for methylation detection. Any disagreement was discussed and reached a consensus for all issues.
statistical analysis
ORs with 95% confidence intervals (CIs) were calculated by using a fixed or random effect model depending on heterogeneity (a fixed effect model for I 2 <50%, a random effect model for I 2 >50%). The analysis was performed to compare DAPK promoter hypermethylation between NSCLC and normal tissue, DAPK promoter hypermethylation in different stage of NSCLC, DAPK promoter hypermethylation in different histology type of NSCLC, as well as in smoker and nonsmoker patients with NSCLC. All P-values were two sided. P-value less than 0.05 was considered statistically significant. Funnel plots were used for detection of publication bias. All analysis was performed with Review Manager 5.2.
Results
In total, 28 studies were included in the present study after screening 304 articles by two reviewers (Figure 1 ). The following items were collected from each study: first author, published year, country, histology of NSCLC, and DAPK hypermethylation status, smoking status as well as patient prognosis ( Table 1) .
The total number of NSCLC tumor from 28 studies is 2148, 870 of them were with DAPK promoter hypermethylated, the rate was 40.50%. Whereas the promoter hypermethylation rate from individual study ranged from 10.99% to 83.13% (Table 1 ). The frequency of DAPK promoter hypermethylation was significantly higher in NSCLC than in non-malignant lung; and the pooled OR was 5.69 with 95% CI 3.44-9.39, Z=6.79, P<0.00001 (Figure 2 2 =0% ( Figure 6 ). The quality of each study was assessed using the Newcastle Ottawa Quality Assessment Scale (NOQAS). This scale for non-randomized case controlled studies and cohort studies was used to allocate a maximum of nine points for the quality of selection, comparability, exposure, and outcomes for study participants. Of the studies, 15 scored eight points, 
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Clinicopathological significance of DAPK promoter methylation in NSCLC 11 scored seven points, and two scored six points (data not shown). Hence, the studies were of a relatively high quality. A sensitivity analysis, in which one study was removed at a time, was conducted to assess the result stability. The pooled ORs were not significantly changed, indicating the stability of our analyses (data not shown). The funnel plots were largely symmetric ( Figure 7 ), suggesting there were no publication biases in the meta-analysis of DAPK promoter hypermethylation and clinicopathological features.
Discussion
Aberrant methylation in tumor suppressor genes has been linked to carcinogenesis. Hypermethylation is the predominant mechanism to make tumor suppressor genes silent by promoter inactivation. DAPK gene is located on chromosome 9q34.1. It encodes a proapoptotic protein involved in apoptosis initiated by THN-α, IFN-γ, Fas, and TRAIL. DAPK promoter methylation has been observed in about 30 types of tumor including NSCLC. Moreover, aggressiveness of malignant tumors has been associated with the methylation of the promoter region of the DAPK gene and loss of DAPK expression. 20 A number of studies evaluated the methylation rate in NSCLC, which ranged from 10.99% to 83.33% due to small size of samples. We pooled 28 studies including 2,148 NSCLC patients, 870 of them were with DAPK gene promoter hypermethylated; hypermethylation rate was 40.50%, 5.69 times higher than the one in non-malignant lung tissue. Therefore, DAPK promoter hypermethylation was correlated with the risk of NSCLC. Previous evidence indicated that the expression of DAPK was partially restored by treatment with a demethylation agent, 5′-aza-2′-deoxycitidine. 15 DAPK could be a potential target for development of new strategy of treatment.
We did not find significant association of DAPK promoter hypermethylation with tumor histology, smoking, 
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Zhang et al and stage. Although TNM staging system still remained the most powerful tool for medical decision making, it is difficult to accurately predict the prognosis for individual patient. The 5-year survival rate for patients with stage I NSCLC is about 65%-80%, 21 therefore a more accurate tool, independent from TNM stage, is very important to predict prognosis in those patients. Our finding indicated that DAPK was correlated to worse survival in our metaanalysis, supporting the importance of epigenetic gene regulation in NSCLC progression and prognosis. Loss of apoptotic functions would compromise cell death induced by unrepaired DNA damage. 22 In addition, DAPK 
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Clinicopathological significance of DAPK promoter methylation in NSCLC promoter hypermethylation is associated with metastatic status. Taken together, DAPK promoter hypermethylation leads to worse prognosis in patients with NSCLC. DAPK hypermethylation is a potential predictor of survival in patients with NSCLC.
Given the important role of smoking in the development of lung cancer and the fact that DNA methylation is an early event in carcinogenesis, 23 several biomarker such as Wnt inhibitory factor-1 (Wif1), Phosphatase and tensin homologue deleted on chromosome 10 (PTEN), and TP53 were associated with smoking behavior. [24] [25] [26] [27] However, no correlation was found between DAPK promoter hypermethylation and the smoking behavior in the present study. Further confirmation needs to be finished in future when more relative studies are available.
Our findings should be interpreted in view of certain limitations. First, most of the included studies were retrospective, 26 out of 28 were of sufficient quality (NOQAS ≥ 7). Hence, the studies were of a relatively high quality. Although the possibility of selection, sample, and publication bias could not be excluded, no obvious bias was detected by the funnel plots. Second, present findings were based on individual unadjusted ORs and further confirmation needs to be finished by evaluation adjusted with other potential risk factors.
Conclusion
In summary, present findings suggested that DAPK promoter hypermethylation was correlated with the risk of NSCLC; and DAPK is a promising drug target for development of new therapy strategy. Additionally, DAPK promoter hypermethylation was a potential predictor of poor prognosis in patients with NSCLC.
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